PURCHASE, N.Y. - Nutrition 21, Inc. today announced that Biosynexus Inc. of Rockville, Md., made a clinical trial milestone payment to Nutrition 21. Biosynexus is Nutrition 21's licensee for nisin and lysostaphin antibacterial technologies for development and marketing of new drugs for human use. Biosynexus develops products for the prevention and treatment of serious bacterial infections.
Biosynexus as a result of initiating a clinical trial, made its first milestone payment to Nutrition 21. The Biosynexus agreements provide for future payments to Nutrition 21 of up to $14 million, contingent upon the achievement by Biosynexus of certain additional milestones; royalties to Nutrition 21 upon commercialization of human drug products from these technologies; and potential other consideration contingent on future transactions between Biosynexus and third parties that relate to nisin or lysostaphin.
Gail Montgomery, Nutrition 21's president and chief executive officer, said, "Our business strategy is to leverage our intellectual property portfolio for maximum return to our shareholders. We are pleased to be working with Biosynexus, who has demonstrated its abilities to further Nutrtion 21's patented technologies, having reached an important milestone in commercializing lysostaphin as a therapy for the prevention and treatment of infections caused by antibiotic resistant bacteria."
According to the Institute of Medicine as many as 100,000 annual deaths are attributable to preventable adverse patient events associated with hospital acquired antibiotic resistant infections, at an estimated cost of $17 billion to $29 billion.
Nutrition 21 is a leading developer and provider of nutritional products whose health benefits are substantiated by clinical research. The market leader in nutritional chromium, Nutrition 21 currently holds 35 patents for nutrition products, 22 for chromium compounds and their uses.
Beyond the Surface: Rethinking Environmental Hygiene Validation at Exchange25
June 30th 2025Environmental hygiene is about more than just shiny surfaces. At Exchange25, infection prevention experts urged the field to look deeper, rethink blame, and validate cleaning efforts across the entire care environment, not just EVS tasks.
A Controversial Reboot: New Vaccine Panel Faces Scrutiny, Support, and Sharp Divides
June 26th 2025As the newly appointed Advisory Committee on Immunization Practices (ACIP) met for the first time under sweeping changes by HHS Secretary Robert F. Kennedy Jr, the national spotlight turned to the panel’s legitimacy, vaccine guidance, and whether science or ideology would steer public health policy in a polarized era.
Getting Down and Dirty With PPE: Presentations at HSPA by Jill Holdsworth and Katie Belski
June 26th 2025In the heart of the hospital, decontamination technicians tackle one of health care’s dirtiest—and most vital—jobs. At HSPA 2025, 6 packed workshops led by experts Jill Holdsworth and Katie Belski spotlighted the crucial, often-overlooked art of PPE removal. The message was clear: proper doffing saves lives, starting with your own.